Crinetics Pharmaceuticals Stock Price on December 16, 2024
| CRNX Stock | USD 53.60 0.86 1.63% |
Below is the normalized historical share price chart for Crinetics Pharmaceuticals extending back to July 18, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Crinetics Pharmaceuticals stands at 53.60, as last reported on the 21st of December, with the highest price reaching 54.25 and the lowest price hitting 51.73 during the day.
If you're considering investing in Crinetics Stock, it is important to understand the factors that can impact its price. At this stage we consider Crinetics Stock to be very steady. Crinetics Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0499, which signifies that the company had a 0.0499% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Crinetics Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please confirm Crinetics Pharmaceuticals' Mean Deviation of 1.86, risk adjusted performance of 0.0149, and Downside Deviation of 3.28 to double-check if the risk estimate we provide is consistent with the expected return of 0.13%.
At this time, Crinetics Pharmaceuticals' Total Stockholder Equity is fairly stable compared to the past year. Common Stock Total Equity is likely to rise to about 406.3 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 33.4 M in 2024. . At this time, Crinetics Pharmaceuticals' Price To Sales Ratio is fairly stable compared to the past year. Price Book Value Ratio is likely to rise to 4.02 in 2024, whereas Price Earnings Ratio is likely to drop (10.11) in 2024. Crinetics Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 18th of July 2018 | 200 Day MA 50.5103 | 50 Day MA 56.9112 | Beta 0.619 |
Crinetics |
Sharpe Ratio = 0.0499
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | CRNX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.58 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Crinetics Pharmaceuticals is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Crinetics Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 5.9563 | Enterprise Value Ebitda (13.40) | Price Sales 4.8 K | Shares Float 91.4 M | Wall Street Target Price 75.0714 |
Crinetics Pharmaceuticals Main Headline on 16th of December 2024
Crinetics Pharmaceuticals Appoints Isabel Kalofonos asChief ... by finance.yahoo.com
SAN DIEGO, Dec. 16, 2024 -- Crinetics Pharmaceuticals, Inc. today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the companys commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the companys deep, innovative pi
Crinetics Pharmaceuticals Valuation on December 16, 2024
It is possible to determine the worth of Crinetics Pharmaceuticals on a given historical date. On December 16, 2024 Crinetics was worth 53.21 at the beginning of the trading date compared to the closed value of 54.63. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Crinetics Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Crinetics Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Crinetics Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Crinetics Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 55.53 | 56.53 | 53.36 | 53.66 | 748,842 | |
12/16/2024 | 53.21 | 54.91 | 52.85 | 54.63 | 1,189,027 |
| 54.23 | 56.15 | 53.04 | 55.37 | 1,032,594 |
| Backtest Crinetics Pharmaceuticals | | | Crinetics Pharmaceuticals History | | | Crinetics Pharmaceuticals Valuation | Previous | Next |
Crinetics Pharmaceuticals Trading Date Momentum on December 16, 2024
| On December 17 2024 Crinetics Pharmaceuticals was traded for 55.37 at the closing time. The top price for the day was 56.15 and the lowest listed price was 53.04 . The trading volume for the day was 1 M. The trading history from December 17, 2024 was a factor to the next trading day price jump. The overall trading delta against the next closing price was 1.35% . The overall trading delta against the current closing price is 4.30% . |
Crinetics Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Crinetics Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Crinetics Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Crinetics financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Crinetics Pharmaceuticals Stock history
Crinetics Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Crinetics is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Crinetics Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Crinetics Pharmaceuticals stock prices may prove useful in developing a viable investing in Crinetics Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 58.1 M | 33.4 M | |
| Net Loss | -147.5 M | -140.1 M |
Crinetics Pharmaceuticals Quarterly Net Working Capital |
|
Crinetics Pharmaceuticals Stock Technical Analysis
Crinetics Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Crinetics Pharmaceuticals Period Price Range
Low | December 21, 2024
| High |
0.00 | 0.00 |
Crinetics Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Crinetics Pharmaceuticals December 21, 2024 Market Strength
Market strength indicators help investors to evaluate how Crinetics Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Crinetics Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Crinetics Pharmaceuticals stock market strength indicators, traders can identify Crinetics Pharmaceuticals entry and exit signals to maximize returns
Crinetics Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Crinetics Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Crinetics Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Crinetics to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0149 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0172 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.